Chen et al. interpreted that sorafenib, which is a multi-kinase inhibitor with activity against VEGFR, PDGFR and RAF kinases, attenuated bleomycin-induced pulmonary fibrosis via prohibition of fibroblast proliferation and EMT33. The gene discussed is PDGFRB; the disease is pulmonary fibrosis.